GVR Report cover Extracorporeal CO2 Removal Devices Market Size, Share & Trends Report

Extracorporeal CO2 Removal Devices Market Size, Share & Trends Analysis Report By Product (Extracorporeal CO2 Machines, Disposables), By Application, By Access, By End-use, By Region, And Segment Forecasts, 2022 - 2030

  • Report ID: GVR-4-68039-636-6
  • Number of Pages: 150
  • Format: Electronic (PDF)
  • Historical Range: 2017 - 2020
  • Industry: Healthcare

Report Overview

The global extracorporeal CO2 removal devices market size was valued at USD 82.8 million in 2021 and is estimated to witness a compound annual growth rate (CAGR) of 7.2% from 2022 to 2030. Rise in ARDS and COPD disorders have led to introduction of novel products for vitalizing blood flow and efficient gas exchange. Increasing regulatory product approval for several extracorporeal removal devices during the COVID-19 times helped various market players to increase their product sales. For instance, in April 2020, Alung Technologies received Emergency Use Authorization (EUA) from the U.S. FDA for Hemolung Respiratory Assist System (RAS) for treatment of COVID-19.

 Japan extracorporeal CO2 removal devices market size, by product, 2020 - 2030 (USD Million)

In recent times, COVID-19 disease caused by the novel coronavirus (SARS-CoV-2) has been a global severe prevalent problem and resulted in thousands of deaths. Respiratory manifestation was one of the main clinical characteristics of this disease; and approximately 15-20% of confirmed and suspected patients required mechanical ventilation and developed severe hypoxemia. The usage of extracorporeal CO2 removal devices has increased since the emergence of COVID-19. However, the number of ECMO machines were in a state of serious shortage for quite a long time during the peak period, along with specific ECCO2R devices. With such increasing demand for extracorporeal CO2 removal devices throughout the world, the market is projected to fuel during the forecast period.

In recent years, several technological improvements and strategies have made it possible to reduce the complexity and size of extracorporeal CO2 removal devices. Such a gradual rise in technological advancements allows ongoing increase in safety and use of these systems. Various technical advances have permitted extracorporeal CO2 removal devices to become feasible and simple, and presently represent further option for support of patients with severe respiratory ailments and high mortality. Thus, technological advancements in extracorporeal CO2 removal devices is anticipated to boost market growth.

Recent technological advances in extracorporeal respiratory assist systems have led to improved interest in extracorporeal carbon dioxide removal (ECCOR) devices. For instance, in November 2021, Alung Technologies received De Novo Clearance for the hemolung respiratory system. This system is the first ECCO2R device approved by the FDA. In November 2020, X-COR Therapeutics closed approximately 2.6 million funding round. This company anticipates to use these funds to continue develop its products including ECCO2R devices.

Extracorporeal CO2 removal devices are used in patients with severe COPD exacerbation and for the establishment of ultraprotective or protective in patients suffering from ARDS. Extracorporeal CO2 removal devices eliminate blood CO2 and fight against the adverse effects of hypercapnia and related acidosis. According to the WHO, COPD has been considered as the third leading cause of death globally and caused about 3.23 million deaths in 2019. In addition, according to the America Lung Association, more than 11 million people get diagnosed with COPD in the U.S. each year. Thus, rising cases of COPD is estimated to boost the adoption of extracorporeal CO2 removal devices, boosting the market growth.

Product Insights

The extracorporeal CO2 machines segment accounted for the largest market share of 52.3% in 2021. Technical simplification has caused the development and potential applications of extracorporeal CO2 extraction devices to progress rapidly, avoiding nearly some of the initial problems associated to ECMO. Extracorporeal CO2 removal devices are theoretically simpler and have fewer personnel as well as logistic requirements, leading to an increased preference among patients. Thus, increasing benefits associated with ECCO2R is anticipated to secure the market position.

The disposables segment is expected to witness a healthy CAGR of 6.80% over the forecast period. Disposables are used per procedures per patient basis in extracorporeal CO2 removal therapy. High consumption and demand for consumables in extracorporeal carbon dioxide removal procedures is predicted to augment the market growth. Hence, increasing need for disposables for several COPD and ARDS-related procedures is anticipated to foster the demand for extracorporeal CO2 removal devices over the analysis period.

Application Insights

The bridge to lung transplant segment accounted for a significant revenue share of 40.7% in 2021. Patients waiting for lung transplantation that develop life-threatening hypercarbia may benefit from extracorporeal CO2 removal devices by using it as a bridge to transplantation. Rising focus of manufacturers such as Alung Technologies, Xenios AG and others on developing extracorporeal CO2 removal devices for bridge to lung transplantation is anticipated to spur the market growth during the forecast period.  

 Global extracorporeal CO2 removal devices market share , by application, 2021 (%)

The ARDS segment has around 21.5% market share in 2021. In patients with ARDS, extracorporeal CO2 removal devices are in much demand owing to its ability to remove CO2 and help enable lung protective ventilation through a reduction in plateau pressures and tidal volumes. Extracorporeal CO2 removal devices aid in management of ARDS and allows more protective ventilation meanwhile eluding extreme levels of respiratory acidosis. ECCO2R devices are considered essential for establishment of protective or ultra-protective ventilation in patients suffering from ARDS. It was also observed that venovenous ECCO2R devices allowed significant reductions in pressure among patients with moderate-to-severe ARDS, thereby surging the product demand.

Access Insights

The venovenous segment held the largest revenue share of 64.2% in 2021. In venovenous access, the blood is drawn from central vein through a drainage cannula using roller or centrifugal pump to produce flow across the gas exchange membrane. In recent years, new generation of extracorporeal CO2 removal devices have been developed. Efficient venovenous extracorporeal CO2 removal devices are made available and are replacing the arterio-venous method, having the benefit of not requiring arterial puncture. Such rise in usage of venovenous extracorporeal CO2 removal devices among patients is predicted to accelerate market growth. 

The arteriovenous segment held a significant market value in 2021. With arteriovenous extracorporeal CO2 removal devices, the blood flows from femoral artery with the help of gas exchanger and returns back into the contralateral femoral vein. Arteriovenous system uses a high-technology, and simplified membrane lung characterized by high gas transfer efficiency, enormously low resistance to blood flow and absence of a heat exchanger. Thus, the above mentioned factors is anticipated to accelerate the market growth.

End-use Insights

The hospitals segment captured the highest market share of 46.1% in 2021. Increasing number of hospital admissions, especially the patients suffering from ARDS due to recent outbreak of COVID-19 is predicted to boost the segment growth.Rising cases of COPD and ARDS is also anticipated to fuel the demand for extracorporeal CO2 removal devices. Rising number of hospitalization of patients coupled with a surge in the number of hospitals across the globe is expected to contribute to market growth during the forecast period

The ambulatory surgical centers segment is predicted to hold a significant market share in 2021. This growth can be accredited to rising prevalence of acute respiratory failure in rural areas having limited access to healthcare services. Also, ambulatory surgical centers offer better patient accessibility, lower out-of-pocket costs and decreased facility costs. Hence, rise in demand for ambulatory surgical centers is anticipated to surge the segment growth. 

Regional Insights 

North America dominated the overall market with a share of around 40% in 2021 owing to the increasing demand for extracorporeal CO2 removal devices among healthcare professionals. Improved healthcare infrastructure and high adoption of extracorporeal CO2 removal devices especially during the COVID-19 pandemic across the U.S. and Canada is projected to contribute towards North America’s market share. Early adoption of novel technologies and large patient pool of ARDS and COPD is anticipated to accelerate the North America market growth. Increasing occurrence of chronic respiratory diseases is anticipated to create demand for extracorporeal CO2 removal devices. Rising preference for safe and rapid minimally invasive ventilation devices have accelerated the growth of extracorporeal CO2 removal devices over the forecast period.

Asia Pacific dominated the market and is anticipated to witness the fastest growth rate of 8.9% during the forecast period. Presence of large patient pool, rising awareness regarding acute respiratory failure, and increasing government healthcare expenditure in developing countries such as India and Japan is predicted to accelerate the regional market growth. Government initiatives, success rate of extracorporeal CO2 removal devices during respiratory surgeries are said to foster the market growth. A huge population base with low per capita income in the Asia Pacific led to high demand for affordable treatment options. Multinational companies are looking forward to investing in developing countries such as China, anticipating the regional market growth.

Extracorporeal CO2 Removal Devices Market Trends by Region

In Europe, the market is expected to have a CAGR of 7.8% during the forecast period. Increasing demand for healthcare devices coupled with rising prevalence of chronic diseases such as respiratory failure in the region are some key drivers for growing market share of this region. Favorable reimbursement policies, increasing government investment in long term healthcare and growing healthcare research infrastructural framework are also boosting the usage rates of extracorporeal CO2 removal devices.

Key Companies & Market Share Insights

Novel product launch, product approval, acquisitions, partnerships, and collaborations are major strategies adopted by major market players to maintain their market share.  For instance, in May 2020, Alung Technologies announced the commercial development of next-generation artificial lung. Hemolung Respiratory Assist System (RAS) extracorporeal CO2 removal devices is manufactured specially for this therapy and widely used as well as simple to use. Some of the prominent players in the extracorporeal CO2 removal devices market include:

  • Medtronic

  • Getinge AB

  • Xenios AG

  • Alung Technologies

  • ESTOR S.P.A

  • Medica Spa

  • Aferectica Srl

Extracorporeal CO2 Removal Devices Market Report Scope

Report Attribute

Details

Market size value in 2022

USD 78.9 million

Revenue forecast in 2030

USD 137.2 million

Growth rate

CAGR of 7.2% from 2022 to 2030

Base year for estimation

2021

Historical data

2017 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million and CAGR from 2022 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, application, access, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; India; Japan; China; Australia; South Korea; Brazil; Mexico; Argentina; Columbia; South Africa, Saudi Arabia, UAE.

Key companies profiled

Medtronic; Getinge AB; Xenios AG; Alung Technologies; ESTOR S.P.A; Medica Spa; Aferectica Srl

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

 

Global Extracorporeal CO2 Removal Devices Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For the purpose of this study, Grand View Research has segmented the global extracorporeal CO2 removal devices market report on the basis of product, application, access, end-use, and region:

Global Extracorporeal CO2 Removal Devices Market Segmentation

  • Product Outlook (Revenue, USD Million, 2017 - 2030)

    • Extracorporeal CO2 machines

    • Disposables

    • Others

  • Application Outlook (Revenue, USD Million, 2017 - 2030)

    • Acute Respiratory Distress Syndrome (ARDS)

    • Chronic Obstructive Pulmonary Disease (COPD)

    • Bridge To Lung Transplant

    • Others

  • Access Outlook (Revenue, USD Million, 2017 - 2030)

    • Venovenous

    • Arteriovenous

  • End-use Outlook (Revenue, USD Million, 2017 - 2030)

    • Hospitals

    • Ambulatory Surgical Centers

    • Clinics

    • Others

  • Regional Outlook (Revenue, USD Million, 2017 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

      • France

      • Italy

      • Spain

    • Asia Pacific

      • China

      • Japan

      • India

      • Australia

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Colombia

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

Frequently Asked Questions About This Report

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.